ClinicalTrials.gg
CompletedNCT04640831Updated Aug 15, 2023

Safety of GH001 in Healthy Volunteers

A Phase 1 interventional study of 5 Methoxy N,N Dimethyltryptamine in Healthy Volunteers, sponsored by GH Research Ireland Limited. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-15.

Sponsored by GH Research Ireland Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Mar 2019, registered Nov 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The aim of the study is to investigate the safety of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT), and its dose-related psychoactive effects in healthy volunteers.

The study will evaluate single, ascending doses of GH001 in Part A and an individualized dosing regimen of GH001 in Part B.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • healthy volunteers
  • 5-MeO-DMT
  • 5-methoxy-dimethyltryptamine
03

In context

Lead sponsor

GH Research Ireland Limited is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a (BMI) in the range of 18.5 and 27.0 kg/m2 (inclusive);
  • Subject is in good general health in the opinion of the medical supervisor;
  • Subject is in good mental health in the opinion of the (clinical) psychologist as determined by the intake interview;

Exclusion criteria

Exclusion Criteria:

  • Has known allergies or or any other to 5-MeO-DMT;
  • Has received any medication within the last 1 month.
  • Has a medically significant condition, which renders the subject unsuitable for the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    GH001 dose A

    Drug: 5 Methoxy N,N Dimethyltryptamine

  • Experimental
    GH001 dose B

    Drug: 5 Methoxy N,N Dimethyltryptamine

  • Experimental
    GH001 dose C

    Drug: 5 Methoxy N,N Dimethyltryptamine

  • Experimental
    GH001 dose D

    Drug: 5 Methoxy N,N Dimethyltryptamine

  • Experimental
    GH001 Individualized Dosing

    Drug: 5 Methoxy N,N Dimethyltryptamine

Interventions

06

What researchers measure

Primary outcomes

  1. The safety and tolerability of GH001

    The safety and tolerability of GH001 is judged by the Study Safety Group based on a combined analysis of reported adverse events, clinical observation, and safety laboratory analyses.

    Time frame: up to 7 days

  2. The dose-related psychoactive effects of GH001 as evaluated by a Visual Analogue Scale

    Visual Analogue Scale scored from 0-100

    Time frame: Retrospectively assessed at 3 hours

07

Study locations

1 site
  • Clinical Trial Site
    Maastricht, Netherlands
08

References and documents

Publications

  • Reckweg J, Mason NL, van Leeuwen C, Toennes SW, Terwey TH, Ramaekers JG. A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers. Front Pharmacol. 2021 Nov 25;12:760671. doi: 10.3389/fphar.2021.760671. eCollection 2021. PubMed 34912222 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Oct 2019, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2020
First posted
Nov 23, 2020
StartActual
Mar 13, 2019
Primary completionActual
Oct 4, 2019
CompletionActual
Oct 4, 2019
Last update
Aug 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04640831
Lead sponsor
GH Research Ireland Limited
Responsible party
Sponsor
First posted
Nov 23, 2020
Start date
Mar 13, 2019
Primary completion
Oct 4, 2019
Completion
Oct 4, 2019
Last update
Aug 15, 2023

Study contacts

GH Research Clinical Team
study director · GH Research Ireland Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methoxydimethyltryptamines

Start the discussion